WO2005014041A3 - Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases - Google Patents

Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases Download PDF

Info

Publication number
WO2005014041A3
WO2005014041A3 PCT/EP2004/008286 EP2004008286W WO2005014041A3 WO 2005014041 A3 WO2005014041 A3 WO 2005014041A3 EP 2004008286 W EP2004008286 W EP 2004008286W WO 2005014041 A3 WO2005014041 A3 WO 2005014041A3
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
dna vaccine
amyloid beta
prevention
treatment
Prior art date
Application number
PCT/EP2004/008286
Other languages
French (fr)
Other versions
WO2005014041A2 (en
Inventor
Yoh Matsumoto
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Yoh Matsumoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Yoh Matsumoto filed Critical Novartis Ag
Publication of WO2005014041A2 publication Critical patent/WO2005014041A2/en
Publication of WO2005014041A3 publication Critical patent/WO2005014041A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Abstract

The present invention relates to methods for the treatment and prevention of neurological and vascular disorders related to beta-amyloid generation, in particular Alzheimer's Disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral haemorrhage with amyloidosis comprising administering an amyloid beta DNA vaccine, especially an amyloid beta DNA vaccine comprising cDNA coding for amyloid beta 1-42 or a fragment thereof; materials, such as pharmaceutical compositions, comprising said amyloid beta DNA vaccine, a process for the preparation of such amyloid beta DNA vaccine; and to methods for identifying an amyloid beta DNA vaccine suitable for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation.
PCT/EP2004/008286 2003-07-24 2004-07-23 Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases WO2005014041A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48963703P 2003-07-24 2003-07-24
US60/489,637 2003-07-24

Publications (2)

Publication Number Publication Date
WO2005014041A2 WO2005014041A2 (en) 2005-02-17
WO2005014041A3 true WO2005014041A3 (en) 2005-05-06

Family

ID=34135098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/008286 WO2005014041A2 (en) 2003-07-24 2004-07-23 Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases

Country Status (1)

Country Link
WO (1) WO2005014041A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US7479550B2 (en) 2006-06-02 2009-01-20 The Board Of Regents Of The University Of Texas System Amyloid β gene vaccines
FR2913886B1 (en) 2007-03-22 2012-03-02 Guerbet Sa USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2167094A2 (en) 2007-06-13 2010-03-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
AU2010228168B2 (en) 2009-03-26 2013-02-21 Yoh Matsumoto DNA vaccine for Alzheimer's disease
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6713640B2 (en) * 2015-10-22 2020-06-24 免疫療法開発株式会社 DNA vaccine against amyloid β and tau
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6582945B1 (en) * 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004050876A1 (en) * 2002-11-29 2004-06-17 Agtc Gene Technology Company Ltd. A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6582945B1 (en) * 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004050876A1 (en) * 2002-11-29 2004-06-17 Agtc Gene Technology Company Ltd. A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200443, Derwent World Patents Index; Class B04, AN 2004-461125, XP002315952 *
GHOCHIKYAN ANAHIT ET AL: "Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 33, no. 12, December 2003 (2003-12-01), pages 3232 - 3241, XP002315950, ISSN: 0014-2980 *
IMBIMBO BRUNO P: "beta-Amyloid immunization approaches for Alzheimer's disease", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, no. 2, June 2002 (2002-06-01), pages 150 - 162, XP002247948, ISSN: 0272-4391 *
SCHILTZ JAN G ET AL: "Antibodies from a DNA peptide vaccination decrease the brain amyliod burden in a mouse model of Alzheimer's disease.", JOURNAL OF MOLECULAR MEDICINE (BERLIN, GERMANY) OCT 2004, vol. 82, no. 10, October 2004 (2004-10-01), pages 706 - 714, XP002315951, ISSN: 0946-2716 *
SIGURDSSON EINAR M ET AL: "Immunization for Alzheimer's disease", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, no. 2, June 2002 (2002-06-01), pages 135 - 142, XP002247946, ISSN: 0272-4391 *
UGEN K E ET AL: "DNA AND PROTEIN BASED VACCINATION SPECIFICALLY STIMULATES T CELL EPITOPES PRESENT WITHIN THE ABETA PEPTIDE VACCINE : A MODEL FOR CELLULAR IMMUNE RESPONSES IN ALZHEIMER'S DISEASE.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, pages Abstract No. 227.2 URL, XP001205149 *

Also Published As

Publication number Publication date
WO2005014041A2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
WO2002016333A3 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
PT2527315E (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
IL191311A (en) Transdermal therapeutic system and use thereof in the manufacture of medicaments for the prevention, treatment or delay of progression of alzheimer's disease, dementia associated with parkinson's disease and symptoms of traumatic brain injury
WO2001060826A3 (en) SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
BG66083B1 (en) Pharmaceutical compositions containing antibodies, and antibodies for prevention andf treatment of amyloidogenic disease
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
DE60045427D1 (en) Bupropin metabolites for the treatment of dementia and other cerebro-vascular diseases
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
IL172229A (en) Use of pyrazolopyridines for the preparation of pharmaceutical compositions for improving perceptive cognition
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
AU2002223170A1 (en) Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
HRP20030953A2 (en) PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase